Agenus (AGEN) Competitors $3.90 -0.03 (-0.76%) (As of 02:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AGEN vs. DTIL, ALGS, SQZ, ADAP, PSTX, LXRX, VNDA, CDXS, RIGL, and ACHVShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Precision BioSciences (DTIL), Aligos Therapeutics (ALGS), SQZ Biotechnologies (SQZ), Adaptimmune Therapeutics (ADAP), Poseida Therapeutics (PSTX), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), and Achieve Life Sciences (ACHV). These companies are all part of the "medical" sector. Agenus vs. Precision BioSciences Aligos Therapeutics SQZ Biotechnologies Adaptimmune Therapeutics Poseida Therapeutics Lexicon Pharmaceuticals Vanda Pharmaceuticals Codexis Rigel Pharmaceuticals Achieve Life Sciences Agenus (NASDAQ:AGEN) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Does the MarketBeat Community believe in AGEN or DTIL? Agenus received 377 more outperform votes than Precision BioSciences when rated by MarketBeat users. Likewise, 69.60% of users gave Agenus an outperform vote while only 67.67% of users gave Precision BioSciences an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46769.60% Underperform Votes20430.40% Precision BioSciencesOutperform Votes9067.67% Underperform Votes4332.33% Which has more volatility and risk, AGEN or DTIL? Agenus has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Which has better earnings and valuation, AGEN or DTIL? Precision BioSciences has lower revenue, but higher earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$156.31M0.54-$245.76M-$11.36-0.35Precision BioSciences$48.73M1.25-$61.32M$0.06140.36 Does the media prefer AGEN or DTIL? In the previous week, Precision BioSciences had 6 more articles in the media than Agenus. MarketBeat recorded 14 mentions for Precision BioSciences and 8 mentions for Agenus. Precision BioSciences' average media sentiment score of 0.17 beat Agenus' score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is AGEN or DTIL more profitable? Precision BioSciences has a net margin of 11.48% compared to Agenus' net margin of -144.94%. Agenus' return on equity of 0.00% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-144.94% N/A -77.23% Precision BioSciences 11.48%-26.58%-6.81% Do insiders and institutionals hold more shares of AGEN or DTIL? 61.5% of Agenus shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 4.6% of Agenus shares are held by insiders. Comparatively, 4.0% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer AGEN or DTIL? Agenus currently has a consensus price target of $10.50, indicating a potential upside of 167.18%. Precision BioSciences has a consensus price target of $39.50, indicating a potential upside of 369.12%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryPrecision BioSciences beats Agenus on 12 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.58M$3.20B$5.27B$8.82BDividend YieldN/A1.76%4.64%4.01%P/E Ratio-0.3512.58119.9616.14Price / Sales0.54325.241,328.52102.19Price / CashN/A147.8838.8934.14Price / Book-0.515.265.825.78Net Income-$245.76M-$42.25M$118.30M$224.20M7 Day Performance-2.96%15.71%4.08%4.17%1 Month Performance-13.63%22.78%11.05%7.85%1 Year Performance-76.61%53.27%39.14%28.75% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus3.8255 of 5 stars$3.90-0.8%$10.50+169.2%-76.0%$84.13M$159.63M-0.34389Upcoming EarningsDTILPrecision BioSciences3.7829 of 5 stars$8.29-8.1%N/A-28.0%$59.94M$48.73M39.87200Analyst RevisionALGSAligos Therapeutics4.5414 of 5 stars$9.48-0.7%N/A-46.1%$30.34M$15.53M-0.4690Analyst ForecastPositive NewsSQZSQZ BiotechnologiesN/A$0.02flatN/A-53.7%$12.83M$18.16M-0.011,620Gap UpADAPAdaptimmune Therapeutics2.2699 of 5 stars$0.83+3.8%N/A+30.4%$211.63M$60.28M-2.36449Upcoming EarningsPSTXPoseida Therapeutics3.7232 of 5 stars$2.53+2.4%N/A+20.1%$245.74M$64.70M-2.13260News CoverageGap UpLXRXLexicon Pharmaceuticals1.9415 of 5 stars$1.21-0.8%N/A+4.0%$296.72M$3.64M-1.54285Upcoming EarningsAnalyst ForecastVNDAVanda Pharmaceuticals4.1316 of 5 stars$4.85+4.1%N/A+13.3%$282.71M$182.02M-25.53203Earnings ReportCDXSCodexis4.2467 of 5 stars$3.49-0.3%N/A+140.2%$247.55M$70.14M-4.01250Gap UpRIGLRigel Pharmaceuticals2.3059 of 5 stars$14.07-0.9%N/A+77.4%$247.49M$116.88M-16.36147News CoverageGap UpACHVAchieve Life Sciences0.7565 of 5 stars$4.74+0.6%N/A+20.2%$162.78MN/A-4.2720News CoverageGap Down Related Companies and Tools Related Companies Precision BioSciences Alternatives Aligos Therapeutics Alternatives SQZ Biotechnologies Alternatives Adaptimmune Therapeutics Alternatives Poseida Therapeutics Alternatives Lexicon Pharmaceuticals Alternatives Vanda Pharmaceuticals Alternatives Codexis Alternatives Rigel Pharmaceuticals Alternatives Achieve Life Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AGEN) was last updated on 11/8/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
